Advertisement

Topics

GW Pharmaceuticals to Report Q3 2015 Financial Results and Host Conference Call on 6 August, 2015

20:00 EDT 22 Jul 2015 | Globe Newswire

LONDON, July 23, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (LSE:GWP), ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 6 August, 2015 its third quarter financial results for the period ending 30 June, 2015. GW will also host a conference call the same day at 8:00 a.m. EDT (1:00 p.m. BST).

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

CONTACT: Enquiries:
         
         GW Pharmaceuticals plc
         (Today)  +44 20 3727 1000
         Stephen Schultz, VP Investor Relations (U.S.)
         917 280 2424 / 401 500 6570
         
         FTI Consulting (Media Enquiries)
         Ben Atwell / Simon Conway / John Dineen (UK)
         + 44 20 3727 1000
         Robert Stanislaro (U.S.)
         212 850 5657
         
         Trout Group, LLC (U.S. investor relations)
         Todd James / Chad Rubin
         646 378 2900

GW Pharmaceuticals plc Logo

NEXT ARTICLE

More From BioPortfolio on "GW Pharmaceuticals to Report Q3 2015 Financial Results and Host Conference Call on 6 August, 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...